FDA Review Yields Clearer Regulatory Path for Spectral Medical’s Sepsis Therapy

Spectral Medical Inc. (EDT.TO), a late-stage theranostic company, has disclosed updates from its 100-day meeting with the U.S. Food and Drug Administration (FDA) concerning Toraymyxin for the treatment of sepsis.

Sepsis is a life-threatening condition characterized by the presence of bacteria in the bloodstream. Standard treatment involves administering high doses of broad-spectrum antibiotics, with a key focus on eliminating endotoxins produced by these organisms from the blood.

Toraymyxin (PMX) is a therapeutic hemoperfusion device developed to remove endotoxins from the blood in sepsis patients. Endotoxin levels are monitored using the company’s Endotoxin Activity Assay (EAA), which has already received FDA clearance.

Spectral submitted a Premarket Approval (PMA) application for Toraymyxin to the FDA, prompting a substantive review of the submitted data. However, shortly before the 100-day meeting, the FDA issued a deficiency letter to Spectral, requesting additional information, analyses, and testing to finalize the review.

According to the company, the 100-day meeting was constructive, providing greater clarity on the outstanding items required by the FDA. Notably, the FDA did not request any additional clinical trials to support the validation of Toraymyxin.

Spectral now intends to proceed with advancing the PMA review based on the items outlined by the FDA, and no delays to the current regulatory timeline are expected.

As of June 30, 2026, Spectral held a cash balance of CAD 803,000.

EDT is currently trading at CAD 1.26 on the Toronto Stock Exchange.

Source link